ndSTAT1-TMD specifically inhibited the transcriptional activity of endogenous STAT1 in Th1 and Th17 cells and showed a therapeutic potential comparable to that of anti-IL-17A antibody when administered to psoriasis and IBD mouse models. Here, IL17A is linked to inflammatory bowel disease.